A phase 1b study of E7386, a CREB-binding protein (CBP)/beta-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.Masafumi Ikeda,Naoya Kato,Shunsuke Kondo,Yoshitaka Inaba,Kazuomi Ueshima,Mitsuhito Sasaki,Hiroaki Kanzaki,Hiroshi Ida,Hiroshi Imaoka,Yasunori Minami,Shuichi Mitsunaga,Naoshi Nishida,Sadahisa Ogasawara,Kazuo Watanabe,Takatoshi Sahara,Nozomi Hayata,Shintaro Yamamuro, Takayuki Kimura,Toshiyuki Tamai,Masatoshi KudoJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
